ALS research feature summarizing new laboratory and preclinical work on a promising targeted therapeutic approach and its potential clinical implications.
Key Takeaways
- Nearly all ALS cases involve mislocalized TDP-43 protein forming toxic cytoplasmic aggregates
- Blocking or deleting a conserved TDP-43 region reduced neuron death while preserving normal protein function
- XL20 crosses the blood-brain barrier, halts TDP-43 aggregation, and extended median mouse survival